Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: We compared the recurrence of hepatocellular carcinoma (HCC) and the survival of patients who received radiofrequency ablation (RFA) after transarterial chemoembolization (TACE) with patients treated with TACE or RFA alone. Methods: This study included 201 patients with HCC, who were consecutively enrolled at Seoul St. Mary’s Hospital between December 2004 and February 2010. Inclusion criteria were a single HCC ≤ 5.0 cm or up to three HCCs ≤ 3.0 cm. We used a propensity score model to compare HCC patients (n = 87) who received RFA after TACE (TACE + RFA) with those who received TACE (n = 71) or RFA alone (n = 43). Results: The median follow-up period was 33.3 months (range, 6.8 to 80.9). The TACE + RFA group showed significantly lower local recurrence than the RFA or TACE groups (hazard ratio [HR], 0.309; 95% confidence interval [CI], 0.130 to 0.736; p = 0.008; and HR, 0.352; 95% CI, 0.158 to 0.787; p = 0.011, respectively). The overall survival was significantly better in the TACE + RFA group compared to the RFA group (HR, 0.422; 95% CI, 0.185 to 0.964; p = 0.041). However, the survival benefit was not different between the TACE + RFA and TACE groups (p = 0.124). Subgroup analysis showed that among patients with a tumor size < 3 cm, the TACE + RFA group had significantly better long-term survival than those in the TACE or RFA groups (p = 0.017, p = 0.004, respectively). Conclusions: TACE + RFA combination treatment showed favorable local recurrence and better overall survival rates in early-stage HCC patients. Patients with tumors < 3 cm are likely to benefit more from TACE + RFA combination treatment. Additional studies are needed for the selection of suitable HCC patients for TACE + RFA treatment.
Abstract
Background/Aims: We compared the recurrence of hepatocellular carcinoma (HCC) and the survival of patients who received radiofrequency ablation (RFA) after transarterial chemoembolization (TACE) with patients treated with TACE or RFA alone. Methods: This study included 201 patients with HCC, who were consecutively enrolled at Seoul St. Mary’s Hospital between December 2004 and February 2010. Inclusion criteria were a single HCC ≤ 5.0 cm or up to three HCCs ≤ 3.0 cm. We used a propensity score model to compare HCC patients (n = 87) who received RFA after TACE (TACE + RFA) with those who received TACE (n = 71) or RFA alone (n = 43). Results: The median follow-up period was 33.3 months (range, 6.8 to 80.9). The TACE + RFA group showed significantly lower local recurrence than the RFA or TACE groups (hazard ratio [HR], 0.309; 95% confidence interval [CI], 0.130 to 0.736; p = 0.008; and HR, 0.352; 95% CI, 0.158 to 0.787; p = 0.011, respectively). The overall survival was significantly better in the TACE + RFA group compared to the RFA group (HR, 0.422; 95% CI, 0.185 to 0.964; p = 0.041). However, the survival benefit was not different between the TACE + RFA and TACE groups (p = 0.124). Subgroup analysis showed that among patients with a tumor size < 3 cm, the TACE + RFA group had significantly better long-term survival than those in the TACE or RFA groups (p = 0.017, p = 0.004, respectively). Conclusions: TACE + RFA combination treatment showed favorable local recurrence and better overall survival rates in early-stage HCC patients. Patients with tumors < 3 cm are likely to benefit more from TACE + RFA combination treatment. Additional studies are needed for the selection of suitable HCC patients for TACE + RFA treatment.
참고문헌 (33)
- Parkin DM, "Estimating the world cancer burden: Globocan 2000", Int J Cancer, 94, pp.153~156 (2001)
- El-Serag HB, "Rising incidence of hepatocellular carcinoma in the United States", N Engl J Med, 340, pp.745~750 (1999)
- Bruix J, "Conclusions of the Barcelona-2000 EASL conference: European Association for the Study of the Liver", J Hepatol, 35, pp.421~430 (2001)
- Lencioni RA, "Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection", Radiology, 228, pp.235~240 (2003)
- Lin SM, "Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm", Gastroenterology, 127, pp.1714~1723 (2004)
- Kagawa T, "Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection", Cancer, 116, pp.3638~3644 (2010)
- Choi D, "Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series", Eur Radiol, 17, pp.684~692 (2007)
- Livraghi T, "Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis:is resection still the treatment of choice?", Hepatology, 47, pp.82~89 (2008)
- N’Kontchou G, "Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis", Hepatology, 50, pp.1475~1483 (2009)
- Bruix J, "Management of hepatocellular carcinoma:an update", Hepatology, 53, pp.1020~1022 (2011)
- Llovet JM, "Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival", Hepatology, 37, pp.429~442 (2003)
- Livraghi T, "Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection", Radiology, 210, pp.655~661 (1993)
- McGhana JP, "Radiofrequency ablation of the liver: current status", AJR Am J Roentgenol, 176, pp.3~16 (2001)
- Livraghi T, "Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions", Radiology, 214, pp.761~768 (2000)
- Dupuy DE, "Image-guided radiofrequency tumor ablation: challenges and opportunities: part II", J Vasc Interv Radiol, 12, pp.1135~1148 (2001)
- Curley SA, "Radiofrequency ablation of malignant liver tumors", Ann Surg Oncol, 10, pp.338~347 (2003)
- Llovet JM, "Design and endpoints of clinical trials in hepatocellular carcinoma", J Natl Cancer Inst, 100, pp.698~711 (2008)
- Bruix J, "Chemoembolization for hepatocellular carcinoma", Gastroenterology, 127(5 Suppl 1), pp.S179~S188 (2004)
- Lencioni R, "Loco-regional treatment of hepatocellular carcinoma", Hepatology, 52, pp.762~773 (2010)
- Golfieri R, "Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small(<5 cm)hepatocellular carcinomas", Hepatology, 53, pp.1580~1589 (2011)
- Akamatsu M, "Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial", Liver Int, 24, pp.625~629 (2004)
- Marelli L, "Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies", Cancer Treat Rev, 32, pp.594~606 (2006)
- Lencioni R, "Modified RECIST(mRECIST)assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
- D’Agostino RB Jr, "Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group", Stat Med, 17, pp.2265~2281 (1998)
- Robins JM, "Marginal structural models and causal inference in epidemiology", Epidemiology, 11, pp.550~560 (2000)
- Sohn MH, "F-18 FDG PET", CT findings of huge cholesterol granuloma in multiple ribs, 2011, pp.36, 942~944
- Ravaioli M, "Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria", Am J Transplant, 8, pp.2547~2557 (2008)
- Chen MS, "A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma", Ann Surg, 243, pp.321~328 (2006)
- Pompili M, "Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation:assessment of efficacy at explant analysis and of safety for tumor recurrence", Liver Transpl, 11, pp.1117~1126 (2005)
- Hsu CY, "Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria:a propensity score analysis", Liver Transpl, 17, pp.556~566 (2011)
- Camma C, "Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study", J Hepatol, 42, pp.535~540 (2005)
- Tateishi R, "Percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1000 cases", Cancer, 103, pp.1201~1209 (2005)
- Ng KK, "Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma", J Gastrointest Surg, 12, pp.183~191 (2008)